Knee arthroscopy is the most common orthopedic procedure worldwide. While incidence of post-arthroscopy venous thromboembolic events (VTE) is low, treatment patterns and patient outcomes have not been described. Patients from the "Registro Informatizado Enfermedad TromboEmbolica" who had confirmed post-arthroscopy VTE were compared to patients with provoked, post bone-fracture, and to patients with unprovoked VTE. Baseline characteristics, presenting signs and symptoms, treatment and outcomes including recurrent VTE, bleeds or death were compared. A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE were identified. Post-arthroscopy patients were younger (49.5 vs. 66 years, P < 0.0001) and had less history of VTE [5.9% vs. 20%, OR 0.26 (0.11-0.59)]. Among patients with isolated DVT, there were fewer proximal DVT in the post-arthroscopy group [40% vs. 86%, OR 0.11 (0.06-0.19)]. Treatment duration was shorter in the post-arthroscopy group (174 ± 140 vs. 311 ± 340 days, P < 0.0001) and more often with DOAC ]. Recurrent VTE occurred in 6.18 (1.96-14.9) and 11.9 (11.0-12.8) per 100 patient years [HR 0.52 (0.16-1.26)] after treatment in the post-arthroscopy and unprovoked groups, respectively. Recurrent VTE occurred in 5.17 (1.31-14.1) per 100 patient years in a separate post bone-fracture group (n = 147), also not statistically different than the post-arthroscopy recurrence rate. After anticoagulation cessation, some patients post-knee arthroscopy develop VTE. While our small sample size precludes drawing firm conclusions, this signal should warrant further research into the optimal treatment duration for these patients, as some patients may be at increased risk for long-term recurrence.
Introduction
Knee arthroscopy is usually an elective procedure, performed in relatively young patients, often without thromboprophylaxis [1] . Importantly, these procedures are common; 4 million knee arthroscopies are performed annually, typically in the outpatient setting [2, 3] . After the procedure 1 3 is done, patients often ambulate on their other leg and are fully ambulatory within a few weeks. However, despite short procedural duration and early ambulation, proximal deep vein thrombosis (DVT) [4, 5] and pulmonary embolism (PE) may occur [6] [7] [8] [9] [10] [11] [12] [13] with fatal PE cases reported [14] [15] [16] . Risk factors for developing venous thromboembolic events (VTE) after these procedures and analysis of prevention methods have been published [1, 5, [17] [18] [19] [20] [21] [22] [23] . However, treatment patterns have not been systematically reported and data regarding patient outcomes are variable [3, 18, 19] . We therefore sought to describe patient characteristics, treatment patterns and outcomes in patients who developed VTE after knee arthroscopy in the "Registro Informatizado Enfermedad TromboEmbolica" (RIETE) [24] . Furthermore, we compared these to patients who developed either provoked, post bone-fracture, or unprovoked VTE within the registry.
Methods
RIETE is a multi-center, multi-national, ongoing prospective registry of confirmed acute VTE that has been populated since March 2001 [24] . RIETE is registered at Clinicaltrials.gov (NCT: 02832245). As of June 2017, over 72,000 patients have been enrolled to the registry, from 179 centers around the world. Importantly, to study the outcomes of patients in real-world practice, RIETE does not mandate specific treatment protocols and treatment is at the discretion of attending physicians at the participating sites. Only patients with at least 3 months of follow-up are included. Data quality is constantly monitored by a contract research organization (CRO). All patients provide oral consent to their participation in the registry, according to the requirements of the Ethics Committee within each participating hospital.
As noted, only objectively confirmed VTE (ultrasonography or venography for DVT, pulmonary angiography or helical computed tomography scan for PE) are included in the registry.
Participating centers have local Institutional Review Board approval with patients providing informed consent for registry enrollment.
VTE groups
Patients who developed VTE between February 2009 and December 2017 within 60 days of knee arthroscopy were compared to: (1) patients with unprovoked VTE; and (2) patients with provoked VTE post bone-fracture. Unprovoked VTE were defined as lacking transient risk factors including recent immobilization > 4 days, recent surgery, estrogen use, pregnancy or puerperium, and recent travel. Post bone fracture VTE was defined as occurring within 60 days of a fracture.
Variables
For each patient, the following information was obtained: demographics, past medical history, history of prior thrombosis and known thrombophilia; signs, symptoms and laboratory data at presentation; treatment including anticoagulation use and type and whether thrombolysis or an inferior vena cava filter were offered; and outcomes during the first 3 months including VTE recurrence, bleeding and mortality.
Outcomes
Major bleeding was defined as occurring in a critical site (retroperitoneal, spinal, or intracranial), bleeding requiring transfusion of 2 or more units of packed red blood cells, or fatal bleeding [25] . Fatal PE was defined as any death occurring within 10 days of confirmed PE without an alternative explanation.
Recurrent DVT was defined as a new episode of symptomatic and objectively confirmed ipsilateral or contralateral DVT. Proximal DVT was defined as occurring in the popliteal vein or in a more proximal vein.
Statistical analysis
Mann-Whitney test and Student t-test were used to compare continuous variables, and categorical variables were compared by the Fisher exact test. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, and a two tailed P value of 0.05 was considered statistically significant. All reported analyses were unadjusted due to the lack of clinical granularity necessary for true adjustment for confounders in the examined clinical scenarios. SPSS software (version 15; SPSS Inc, Chicago, IL) was used for statistical management of the data.
Results
A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE were identified.
Post-arthroscopy patients were younger (49.5 vs. 66 years, P < 0.0001), more often male [68% vs. 55%, OR VTE. One average VTE occurred within 22.3 ± 17.1 days of surgery; 71% of patients with VTE after arthroscopy had received pharmacologic prophylaxis, for an average of 12.1 ± 7.9 days. There was no difference in the rate of known thrombophilia between groups (2.0% vs. 3.4%).
About half of the patients in both groups presented with PE (49% and 57%, for the post-arthroscopy and unprovoked groups, respectively). Among patients with isolated PE, a minority of patients in both groups presented with hypotension (4.1% and 2.4%) or syncope (18% and 15%). Among patients with isolated DVT, there were fewer proximal DVT in the post-arthroscopy group [40% vs. 86%, OR 0.11 (0.06-0.19)]. Otherwise, presentation was similar between groups (Table 2) .
Nearly all patients in each group were treated with anticoagulation initially. Treatment duration was shorter in the post-arthroscopy group (173.8 ± 140 days vs. 311.1 ± 340.3 days, P < 0.0001) and more often with direct oral anticoagulants (DOAC) initially [OR 3.67 (1.95-6.89)], and at 3 months [OR 2.67 (1.71-4.18)] (Table 3) .
During treatment with anticoagulation, recurrent VTE occurred in 1.97 (0.10-9.73) and 2.33 (2.11-2.58) per 100 patient years in the post-arthroscopy and unprovoked groups, respectively (Table 4 ). There were no major bleeds in the post-arthroscopy group and there were 2.31 (2.09-2.56) per 100 patient years in the unprovoked group.
Follow-up was available for 56 and 6,410 patients, in the post-arthroscopy and unprovoked groups, respectively (Table 5 ). After treatment was stopped, recurrent VTE occurred in 6.18 (1.96-14.9) and 11.9 (11.0-12.8) per 100 patient years in the post-arthroscopy and in the unprovoked groups, respectively HR 0.52 (0.16-1.26).
Comparison to patients with post-bone fracture VTE
There were 147 patients with post bone-fracture VTE. These patients were older (55.4 vs. 49.5 years, P < 0.01), and more were diabetic (6.8% vs. 1%, P < 0.05) compared to patients with post-arthroscopy VTE. Otherwise baseline characteristics and presentation were similar. Treatment patterns were also similar, though fewer patients in the post bonefracture group received DOAC (15% vs. 26%, P < 0.05). The mean duration of therapy post bone-fracture was 215.3 ± 258.5 days. During treatment with anticoagulation mortality occurred in 7.3 (2.96-15.2) per 100 patient years in the post bone-fracture group, while none of the patient in the post-arthroscopy group had died (P < 0.05). Otherwise, outcomes during treatment with anticoagulation and after anticoagulation was stopped were similar between patients in both groups.
Discussion
In this first systematic analysis of post knee-arthroscopy VTE, most patients had a benign presentation including distal DVT or low-risk PE. Nonetheless, in absolute terms the incidence of syncope was still high. Treatment typically included anticoagulation and adverse events during treatment were uncommon. While recurrent VTE did occur once anticoagulation was stopped, we could not identify differences in event rates in comparison to patients with a clearly provoked or unprovoked VTE. However, drawing firm conclusions may not be possible given our small sample size. Descriptions of post-arthroscopy VTE treatment and outcomes are lacking in the literature. Several case-reports have reported fatal PE post knee-arthroscopy [15, 16] . In a retrospective series of 102 patients undergoing knee arthroscopy, 8 developed calf-DVT and at a median of 118 days 50% had auto-lysed, while 1 had propagated to the popliteal vein [1] . In the Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA) study 120 patients undergoing knee-arthroscopy received prophylaxis with rivaroxaban and were compared to 119 patients who received placebo [19] . While the study reported outcomes for all patients, 7 patients in the placebo arm developed proximal (n = 1) or distal (n = 6) DVT while 1 patient in the study arm developed distal DVT (P = 0.03). Treatment was not reported, however none of the patients developed PE or died. Similarly, in the largest study to-date where 1327 patients undergoing knee-arthroscopy were randomized to receive low molecular weight heparin or placebo for thromboprophylaxis, at 3 months the incidence of VTE was 0.6% in the treatment arm and 0.4% in the control arm and while treatment was not detailed, no deaths were noted [3] . In contrast, the current study included only patients who have already sustained a VTE. We report management and outcomes. In order to provide context, we compared post-arthroscopy VTE to two separate cohorts: those with clearly unprovoked VTE and those with provoked VTE after bone-fracture. On average, treatment was longer than 6 months; more than the typical duration of therapy for provoked events [26] . While more patients in the post-arthroscopy group received a DOAC, it should be noted that this did not reflect differences in availability as most patients were recruited over similar timeframes. During the course of anticoagulation, there were no differences in the rate of patients who developed VTE recurrences between patients with post-arthroscopy and either comparison group. While firm conclusions cannot be drawn, some patients did have recurrent VTE once anticoagulation was stopped. In absolute terms the recurrence rate was lower than in the unprovoked group, however not in a statistically significant manner. But, recurrent events were also noted in patients with post-fracture VTE. This is in contrast to published recurrence rates for provoked VTE [27] .
Strengths of the current study include the detailed description of treatment and outcomes during and after anticoagulation. However, our study has limitations. As there were very few outcomes in the post-arthroscopy group, we cannot comment about the association of baseline characteristics and outcomes. We could not report on specific procedural data; however increased procedural risk was demonstrated across all indications of knee arthroscopy [10] . Finally, we only reported symptomatic events. Proactive surveillance may detect patients with asymptomatic DVT [1, 4, 19] . However, this practice may over-estimate the incidence of DVT [3, 5] and may result in treatment-related complications [14] . Furthermore, by reporting only symptomatic events our results reflect clinical practice [3, 21, 28] .
Conclusions
In this largest study to date examining post-knee arthroscopy VTE treatment and outcomes, there were few thrombotic complications during anticoagulation. Recurrent VTE did occur in some patients after anticoagulation cessation. Our small sample size and low event rate preclude drawing strong conclusions, however this signal should warrant further investigation into the optimal treatment duration for these patients as long-term prevention may be warranted for some.
